Viewing Study NCT02332512

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 11:07 AM
Ignite Modification Date: 2026-02-25 @ 9:48 PM
Study NCT ID: NCT02332512
Status: UNKNOWN
Last Update Posted: 2017-02-24
First Post: 2015-01-04
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Non-Small-Cell Lung View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-squamous non-small cell lung cancer View
None Wild-type EGFR View
None 3rd/4th line treatment View
None apatinib View